03:37 PM EST - Akela Pharma, Inc. : announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC. In addition, the Company also announced the termination of its Fentanyl Taifun drug development program by its Japanese partner, Teikoku Seiyaku, Co., Ltd., and the initiation of bankruptcy proceedings for the Company's Finnish subsidiary. Akela Pharma, Inc.
shares T.AKL are trading up $0.005 at $0.17.
